Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Knight Therapeutics Inc (GUD.TO)

Knight Therapeutics Inc (GUD.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 937,030
  • Shares Outstanding, K 133,480
  • Annual Sales, $ 47,461 K
  • Annual Income, $ 14,517 K
  • 60-Month Beta 0.76
  • Price/Sales 10.74
  • Price/Cash Flow N/A
  • Price/Book 1.20
  • Price/Earnings ttm 140.40
  • Earnings Per Share ttm 0.05
  • Most Recent Earnings -0.01 on 03/31/20
  • Next Earnings Date 08/13/20
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.00
  • Number of Estimates 2
  • High Estimate 0.01
  • Low Estimate -0.01
  • Prior Year 0.13
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.51 +7.83%
on 06/26/20
7.71 -8.95%
on 06/01/20
-0.59 (-7.75%)
since 05/29/20
3-Month
6.03 +16.42%
on 04/01/20
8.08 -13.12%
on 04/24/20
+0.89 (+14.52%)
since 03/30/20
52-Week
4.73 +48.41%
on 03/19/20
8.88 -20.95%
on 10/23/19
-0.70 (-9.07%)
since 06/28/19

Most Recent Stories

More News
Knight Therapeutics Reports First Quarter 2020 Results

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company"), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31,...

KHTRF : 5.1000 (-4.67%)
GUD.TO : 7.02 (+0.29%)
Knight Therapeutics Inc. announces voting results from the Annual Meeting

Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the voting results from the Annual Meeting of the Shareholders...

KHTRF : 5.1000 (-4.67%)
GUD.TO : 7.02 (+0.29%)
Notice of Knight Therapeutics' First Quarter 2020 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2020 financial results on Friday, June 26, 2020 prior to...

KHTRF : 5.1000 (-4.67%)
GUD.TO : 7.02 (+0.29%)
Knight Therapeutics Inc. Announces Further Update on Extension of First Quarter 2020 Filings due to COVID-19

Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"), a leading pan-American (ex USA) specialty pharmaceutical company, announced today, further to its news release dated April 30, 2020, that...

KHTRF : 5.1000 (-4.67%)
GUD.TO : 7.02 (+0.29%)
Knight to Present at the Jefferies 2020 Virtual Global Healthcare Conference

Knight Therapeutics Inc. (TSX: GUD), a leading pan-American (ex- US) specialty pharmaceutical company, announced today that Samira Sakhia, President, is scheduled to present at the Jefferies 2020 Virtual...

KHTRF : 5.1000 (-4.67%)
GUD.TO : 7.02 (+0.29%)
Knight Therapeutics Inc. Announces Extension of First Quarter 2020 Filings due to COVID-19

Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"), a leading pan-American (ex USA) specialty pharmaceutical company, announced today that as a result of the COVID-19 impact, Knight will be...

KHTRF : 5.1000 (-4.67%)
GUD.TO : 7.02 (+0.29%)
Knight Announces the Re-Launch of Trelstar(R) in Canada

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has successfully taken over commercial activities from Debiopharm's previous...

KHTRF : 5.1000 (-4.67%)
GUD.TO : 7.02 (+0.29%)
Knight Therapeutics Announces Approval of IBSRELA(TM) in Canada

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced that Health Canada has approved IBSRELA(TM) (tenapanor) for the treatment of irritable...

KHTRF : 5.1000 (-4.67%)
GUD.TO : 7.02 (+0.29%)
ARDX : 6.83 (-1.30%)
Knight Therapeutics Inc. Announces Triumvira Loan Repayment

Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, announced today that privately-held Triumvira Immunologics Inc. ("Triumvira") has repaid...

KHTRF : 5.1000 (-4.67%)
GUD.TO : 7.02 (+0.29%)
Knight Therapeutics Inc. Announces Completion of its Normal Course Issuer Bid

Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "), a leading pan-American (ex-USA) specialty pharmaceutical company, is pleased to announce the completion of its Normal Course Issuer Bid...

KHTRF : 5.1000 (-4.67%)
GUD.TO : 7.02 (+0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

2nd Resistance Point 7.10
1st Resistance Point 7.06
Last Price 7.02
1st Support Level 6.96
2nd Support Level 6.90

See More

52-Week High 8.88
Fibonacci 61.8% 7.29
Last Price 7.02
Fibonacci 50% 6.81
Fibonacci 38.2% 6.32
52-Week Low 4.73

See More

Business Summary

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar